Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec;203(5):701-703.
doi: 10.1111/bjh.19095. Epub 2023 Sep 24.

Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect

Katharine L Lewis  1   2   3 , Chan Y Cheah  1   2   3
Affiliations
Comment

Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect

Katharine L Lewis et al. Br J Haematol. 2023 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D, et al. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023;64(2):371-377.
    1. Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Giné E, et al. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022;140(17):1907-1916.
    1. Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139(15):2306-2315.
    1. Ghafouri S, Timmerman J, Larson S, Mead MD. Axicabtagene ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? Bone Marrow Transplant. 2021;56(4):974-977.
    1. Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021;5(24):5626-5630.

Substances

LinkOut - more resources